ReviewTranslational lung cancer research2025
Opportunities and challenges in lung cancer care in the era of large language models and vision language models.
Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Hybrid Curriculum Learning for Data-Efficient Lung Nodule Detection with YOLOv11.Diagnostics (Basel, Switzerland) · 2026Article
- Benchmarking Large Language Models Using a Best Evidence Topic Report in a Patient With Early Non-Small Cell Lung Cancer.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Advancements in artificial intelligence for cancer diagnosis and prognosis prediction: current applications and emerging opportunities.Frontiers in cell and developmental biology · 2026Review
- A Language Vision Model Approach for Automated Tumor Contouring in Radiation Oncology.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lung cancer remains the leading cause of cancer-related deaths globally. Over the past decade, the development of artificial intelligence (AI) has significantly propelled lung cancer care, particularly in areas such as lung cancer early diagnosis, survival prediction, recurrence prediction, medical image processing, medical image registration, medical visual question answering, clinical report writing, medical image generation, and multimodal integration. This review aims to provide a comprehensive summary of the various AI methods utilized in lung cancer care, with a particular emphasis on machine learning and deep learning techniques. Moreover, with the advent and widespread application of large language models (LLMs), vision language models (VLMs), and multimodal integration for downstream clinical tasks, we explore the current landscape these cutting-edge AI tools offer. However, it also presents both significant challenges and opportunities, including data privacy risks, inherent biases that may exacerbate healthcare disparities, model hallucinations, ethical implications, implementation costs, and the lack of standardized evaluation metrics. Furthermore, the translation of these technologies from experimental research to clinical implementation demands comprehensive validation protocols and multidisciplinary collaboration to guarantee patient safety, therapeutic efficacy, and equitable healthcare delivery. This review emphasizes the critical role of AI in enhancing our understanding and management of lung cancer, ultimately striving for precision medicine and equitable healthcare worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.